AnaptysBio ANAB 深 沪
等待开盘 09-30 09:30:00 美东时间
23.27
-0.310
-1.31%
华盛通- 最 高24.10
- 今 开23.54
- 成交量 47.43万股
- 最 低 23.15
- 昨 收 23.58
- 总市值 6.51亿
- 52周最高 36.54
- 市盈率 静 --
- 换手率 1.69%
- 52周最低 12.21
- 委 比 -26.10%
- 总股本 2799.70万
- 历史最高 134.00
- 量 比 0.94
- 振 幅 4.03%
- 历史最低 10.00
- 每 手 1
- 风险率 5.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stocks to Watch: AnaptysBio, Firefly Aerospace, Progress Software
Unity Software(U.US) reported fourth-quarter financial results after the market...
今天 07:26
AnaptysBio splits operations into two companies
AnaptysBio (NASDAQ:ANAB) has announced plans to split its operations into two separate publicly traded companies. The first company will focus on managing royalties and milestone payments from partner...
今天 05:32
AnaptysBio Announces Business Separation Plans
AnaptysBio ( ($ANAB) ) has shared an announcement. On September 29, 2025, Anapt...
今天 05:04
AnaptysBio Intends To Separate Biopharma Business By 2026; Plans To Operate Business As Two Public Companies
Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and
今天 04:09
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
AnaptysBio to host virtual investor event on ANB033, its CD122 antagonist, on Oct 14. The event will feature Joseph A. Murray, M.D., and Anaptys management, covering ANB033's mechanism, preclinical data, Phase 1a results, celiac disease biology, and Phase 1b trial design. A live webcast and replay will be available on Anaptys' investor website. ANB033 targets CD122 to reduce pathogenic immune cells, with a Phase 1b trial ongoing for celiac diseas...
09-29 20:05
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
AnaptysBio, Inc. announced plans to split into two independent, publicly traded companies: Royalty Management Co, focused on managing royalties from collaborations with GSK and Vanda, and Biopharma Co, focused on developing innovative immunology therapeutics like rosnilimab, ANB033, and ANB101. The separation is expected to be completed by year-end 2026. An investor conference call is scheduled for Sept. 29, 2025, at 4:30pm ET/1:30pm PT.
09-29 20:05
Anaptys Announces Participation in September Investor Conferences
AnaptysBio, a clinical-stage biotechnology company, announced that its executives will attend three investor conferences: the Cantor Global Healthcare Conference on Sept. 3, the Wells Fargo Healthcare Conference on Sept. 4, and the Stifel Virtual Immunology and Inflammation Forum on Sept. 16. Each event will feature fireside chats and one-on-one meetings. The company focuses on immunology therapeutics, with a lead program, rosnilimab, in Phase 2 ...
08-27 20:15
Wedbush Maintains Outperform on AnaptysBio, Raises Price Target to $45
Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $40 to $45.
08-07 20:45
AnaptysBio Q2 EPS $(1.34) Beats $(1.52) Estimate, Sales $22.263M Beat $11.552M Estimate
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.52) by 11.61 percent. This is a 21.64 percent increase over losses of $(1.71) per share from the
08-07 05:07
Analyst Expectations For AnaptysBio's Future
Across the recent three months, 5 analysts have shared their insights on Anapty...
07-25 02:00
